CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity

PURPOSE: Paclitaxel is used for the treatment of several solid tumors and displays a high inter-individual variation in exposure and toxicity. Neurotoxicity is one of the most prominent side-effects of paclitaxel. This study explores potential predictive pharmacokinetic and pharmacogenetic determina...

Full description

Saved in:

Bibliographic Details
Main Authors:	de Graan, Anne-Joy M., Elens, Laure, Sprowl, Jason A., Sparreboom, Alex, Friberg, Lena E., van der Holt, Bronno, de Raaf, Pleun J., de Bruijn, Peter, Engels, Frederike K., Eskens, Ferry A.L.M., Wiemer, Erik A.C., Verweij, Jaap, Mathijssen, Ron H.J., van Schaik, Ron H.N.
Format:	Artigo
Language:	Inglês
Published:	2013
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3686845/ https://ncbi.nlm.nih.gov/pubmed/23640974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3786
Tags:	Add Tag No Tags, Be the first to tag this record!

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity

Similar Items